Aurélie Mahalatchimy
Présentation
Aurélie Mahalatchimy is an academic lawyer (PhD in law from the University of Toulouse, France). She is permanent Researcher at the French National Centre for Scientific Research (CNRS, chargée de recherche), Aix Marseille University, Toulon University, Pau & Pays AdourUniversity, International, Comparative and European laws (DICE- CERIC) research lab, Aix-en-Provence, France. She is also Associated researcher to the Centre for Global Health Policy, School of Global Studies, University of Sussex, UK. Aurélie’smain research interest is International, European and Comparative law of biomedical innovations, especially the uses of human genes, cells and tissues for therapeutic (advanced therapy medicinal products), scientific, commercial and industrial purposes. She has been involved in various International, European, French and UK research projects. She published 52 articles, including 23 in peer-reviewed journals, co-coordinated a special issue of the French review Quaderni on Human as therapeutics, and presented 50 communications, including 13 as invited speaker.
Publications
Publications
|
|
Transhumanisme : de nouveaux droits ?DICE Éditions. DICE Éditions, 22, pp.281, 2024, Confluence des droits, DICE Editions, 979-10-97578-23-7. ⟨10.4000/11zci⟩ |
Le biodroit comme modèle des nouveaux enjeux prioritaires du droit pharmaceutique de l’Union européenneMaria FARTUNOVA-MICHEL; Béligh NABLI. Quel biodroit pour l’Union européenne ?, Bruylant; Larcier, pp.243- 274, 2025, Collection droit de l'Union européenne - Colloques, 9782802776185 |
|
49 - The Regulatory Framework for CAR-T Cells in Europe: Current Status and Foreseeable ChangesEBMT; GoCART Coalition; EHA. The EU CAR-T Handbook, Open Access, , 50- Chapter 49, 2025 |
|
Propos introductifsDICE Éditions. Transhumanisme : de nouveaux droits ?, 22, DICE Éditions, pp.15-31, 2024, Confluence des droits, 979-10-97578-23-7. ⟨10.4000/11zbz⟩ |
|
Du transhumain au posthumain : quels droits fondamentaux ?DICE Éditions. Transhumanisme : de nouveaux droits ?, 22, DICE Éditions, pp.103-124, 2024, Confluence des droits, 979-10-97578-23-7. ⟨10.4000/11zc5⟩ |
|
|
|
Les droits fondamentaux comme frontières de la médecine améliorative de l'humain : l'application du principe d'égalitéAmandine Cayol; Bénédicte Bévière-Boyer; Wei Wang; Emilie Gaillard. Le transhumanisme à l'ère de la médecine améliorative, mare & martin, pp.309-329, 2024, Collection de la Chaire d’excellence CNRS : Normandie pour la Paix, 978-2-84934-832-1 |
Regulation of Genome Editing in Human iPS Cells: FranceHans-Georg Dederer; Gregor Frenken. Genome Editing in Human iPS Cells: A Comparative Legal Analysis of National Regulatory Frameworks for iPSC-based Cell/Gene Therapies, Springer, pp.83-106, 2022, 978-3-030-93022-6. ⟨10.1007/978-3-030-93023-3_4⟩ |
|
|
|
Regulating Medical Devices in the European UnionThe Oxford Handbook of Comparative Health Law Edited by David Orentlicher and Tamara Hervey, Oxford University Press, 2020, ⟨10.1093/oxfordhb/9780190846756.013.58⟩ |
|
|
Regulating Medicines in the European UnionThe Oxford Handbook of Comparative Health Law Edited by David Orentlicher and Tamara Hervey, Oxford University Press, 2020, ⟨10.1093/oxfordhb/9780190846756.013.24⟩ |
|
|
Le génome humain édité : risques et gouvernanceN. De Grove-Valdeyron (dir.), Innovation et Analyse des risques dans le domaine de la santé et des produits de santé dans l'Union Européenne : regards croisés, 2020 |
|
|
Introduction to Medical Products LawThe Oxford Handbook of Comparative Health Law Edited by David Orentlicher and Tamara Hervey, Oxford University Press, 2020, ⟨10.1093/oxfordhb/9780190846756.013.57⟩ |
|
|
Ethical and legal frameworks for embryonic stem-cell based research in France and in Europe: a challenge for biotechnologyCUPL. Biotechnology Medicine and Law, 2018, 978-7-5620-8420-4 |
|
|
In need for a modern Daedalus? The challenging regulatory path for marketing gene therapy medicinal products in China and EuropeQ. Yanping, A.-M. Duguet. Biotechnology Medicine and Law, China University of Political Science and Law Press, 2018, 978-7-5620-8420-4 |
EU law and policy on human materialsT. K. HERVEY; C. A. YOUNG. Research Handbook in EU Health Law and Policy, Edward Elgar Publishing, pp.222- 241, 2017, 978 1 78536 471 6 |
|
EU law and policy on new health technologiesT. K. HERVEY; C. A. YOUNG. Research Handbook in EU Health Law and Policy, Edward Elgar Publishing, pp.197- 221, 2017, 978 1 78536 471 6 |
|
Legal and ethical issues in European projects MeDALL & EuroTARGET dealing with biomarkersAnne- Marie Duguet. Aspects légaux et éthiques du commencement de la vie, Séminaire d'actualité de droit médical, Les Etudes Hospitalières, pp.307- 317, 2015, 978-2-84874-587-9 |
|
Recherche et maladies rares, le cas des mineurs: principes éthiques et protection des sujets vulnérablesIsabelle Poirot- Mazères; Paul Gimenes. Les maladies rares, une voie pour la santé de demain, Actes et séminaires, LEH Edition, pp.111- 120, 2015, 978-2-84874-579-4 |
|
Le consentement éclairé dans la recherche pédiatrique : aspects internationauxSous la direction de l'Association française de droit de la santé, Anne Laude, Président. Consentement et santé, Dalloz, pp.321-332, 2014, 978-2247134298 |
|
Risques et médicaments de thérapie innovante : quelle règlementation en droit de l’Union européenne ?Nathalie De Grove- Valdeyron. La sécurité des produits de santé dans l'Union européenne, Etudes de l’Institut de Recherche en droit Européen International et Comparé, Presses de l’Université des Sciences Sociales de Toulouse, pp.73- 110, 2014, 978-2-36170-091-1 |
|
Legal, ethical and social issues in longitudinal studies involving children. An example: The MeDALL projectAnne- Marie Duguet. Actions pour la santé et la recherche médicale en faveur des personnes vulnérables et des pays émergents, Séminaire d’actualité de droit médical, Les Etudes Hospitalières, pp.297-308, 2012, 978-2-84874-378-3 |
|
L'accès aux biotechnologies dans l'Union Européenne: mesures d'incitation et limitesAnne- Marie Duguet; Isabelle Filippi; Louise Deffrennes. Droit des patients, mobilité et accès aux soins, Séminaire d’actualité de droit médical, Les Etudes Hospitalières, pp.161-171, 2011, 9782848742502 |
|
Ethical issues linked to inequality of access aspects to transplantation and accompanying treatments throughout EuropeAnne- Marie Duguet; Isabelle Filippi; Louise Deffrennes. Droit des patients, mobilité et accès aux soins, Séminaire d’actualité de droit médical, Les Etudes Hospitalières, pp.209-220, 2011, 9782848742502 |
|
L'accès aux médicaments orphelins dans l'Union européenneAnne-Marie Duguet; Isabelle Filippi. Droit de la santé publique dans un contexte transnational, Séminaire d'actualité de droit médical, Les Etudes Hospitalières, pp.407-422, 2010, 978-2-84874-146-8 |
|
A new proposal to help researchers in the respect of legal requirements for the exchange of human biological materialJane Kaye; Mark Stranger. Principles and Practice in Biobank Governance, Ashgate, pp.191-200, 2009, 9781409492108 |
|
Judicial aspects of the advanced therapies’ clinical assays for the graftAnne-Marie Duguet; Isabelle Filippi; Jean Herveg. Accès aux transplantations d’organes et de tissus en Europe, et droits aux soins en Europe, Séminaire d'actualité de droit médical, Les Etudes Hospitalières, pp.159-171, 2009, 978-2-84874-121-5 |
|
Aspects juridiques des essais cliniques des thérapies innovantes pour les greffes (Ré- édition)Marc Blanquet; Nathalie De Grove-Valdeyron. Etudes de droit communautaire de la santé et du médicament, Etudes de l’Institut de Recherche en droit Européen International et Comparé (V), Presses de l’Université des Sciences Sociales de Toulouse, pp.169-189, 2009, 978-2-915699-84-5 |
Substances of human origin in CJEU case-law: fragmentation and defragmentationWorkshop “Fragmentation and defragmentation of the law on biomedical innovations”, UMR 7318 DICE CERIC, CNRS, Aix-Marseille University; Law for Health and Life, University of Amsterdam, Oct 2025, Amsterdam, Netherlands |
|
Rapporteur invité du workshop “Medicines Justice Requires Transparent Medicines Evidence Communication: Why, for Whom, and How?” en conférence plénièreBuilding Bridges for Medicines Justice, Law for Health and Life, Faculty of Law, University of Amsterdam, Oct 2025, Amsterdam, Netherlands |
|
Introduction and chairing of the EuroGCT Lunchtime Symposium on "Policy and regulatory strategies: current and prospective impact on gene and cell therapy developmentEuropean Society of Gene & Cell Therapy 2025, ESGCT, Oct 2025, Sevilla, Spain |
|
Rapporteur invité du workshop “Regulatory decision making and the roles of evidence, values and patient participation” en conférence plénièreBuilding Bridges for Medicines Justice, Law for Health and Life, Faculty of Law, University of Amsterdam, Oct 2025, Amsterdam, Netherlands |
|
Biological medicines as a model for the general European legislation on medicinal productsWorkshop “Fragmentation and defragmentation of the law on biomedical innovations”, UMR 7318 DICE CERIC, CNRS, Aix-Marseille University; Law for Health and Life, University of Amsterdam, Oct 2025, Amsterdam, Netherlands |
|
Introduction of the Workshop “Fragmentation and defragmentation of the law on biomedical innovations”Workshop “Fragmentation and defragmentation of the law on biomedical innovations”, UMR 7318 DICE CERIC, CNRS, Aix-Marseille University; Law for Health and Life, University of Amsterdam, Oct 2025, Amsterdam, Netherlands |
|
Introduction and Chairing of the EuroGCT Workshop on “Is the EU Regulation on HTA Enhancing Equitable Access to Innovative Medicines in Europe? A EuroGCT workshop”Building Bridges for Medicines Justice, Law for Health and Life, Faculty of Law, University of Amsterdam, Oct 2025, Amsterdam, Netherlands |
|
Some thoughts on strategies for drafting clear, adaptable guidance for genome editing based medicinesRegulatory Frameworks and Clinical Applications in Gene Editing: Formulating Guidelines and Industrial Agreements, European COST action "Genome Editing to Treat Human Diseases" (COST Action GenE-HumDi), Oct 2025, Sevilla, Spain |
|
Wide communication of research results: The EuroGCT projectWorkshop “Fragmentation and defragmentation of the law on biomedical innovations”, UMR 7318 DICE CERIC, CNRS, Aix-Marseille University; Law for Health and Life, University of Amsterdam, Oct 2025, Amsterdam, Netherlands |
|
Fragmentation and Defragmentation in EU Law on Innovative Biomedicine: Revealing Dialectic Mechanisms of Legal IntegrationWorkshop “Fragmentation and defragmentation of the law on biomedical innovations”, UMR 7318 DICE CERIC, CNRS, Aix-Marseille University; Law for Health and Life, University of Amsterdam, Oct 2025, Amsterdam, Netherlands |
|
Fragmentation and defragmentation of the European law on biomedical innovation in EU guidanceWorkshop “Fragmentation and defragmentation of the law on biomedical innovations”, UMR 7318 DICE CERIC, CNRS, Aix-Marseille University; Law for Health and Life, University of Amsterdam, Oct 2025, Amsterdam, Netherlands |
|
Des frontières en mouvement: la fragmentation et la défragmentation du droit européen des innovations biomédicalesAux frontières du droit de la santé, Estelle Brosset (CERIC) et Guylène Nicolas (CDSA), Nov 2025, Aix-en-Provence, France |
|
Roundtable on “Accelerating Cell and Gene Therapy Innovation: Regulatory Pathways in Europe”Advanced Therapies Europe 2024, Advanced Therapies Europe 2024, Sep 2024, Estoril (Portugal), Portugal |
|
Strengthening the quality and safety of Substance of Human Origin: what impact on fundamental rights?European Association of Health Law 2024, EAHL, University of Warsaw, Sep 2024, Warsaw, Poland |
|
The rise of the secretome: A comparative analysis of the governance of secretome-based interventions between Canada and the European UnionEuropean Association of Health Law 2024, European Association of Health Law 2024, Sep 2024, Warsaw (POLAND), Poland |
|
Biomedical innovations in EU non- binding lawWorkshop I-BioLex on “Definitions and regulatory concepts in biolaw”, Aurélie Mahalatchimy; Xavier Magnon; Marie Glinel, Apr 2024, Aix-en -Provence, France |
|
Biomedical innovations in EU binding lawWorkshop I-BioLex on “Definitions and regulatory concepts in biolaw”, Aurélie Mahalatchimy; Xavier Magnon; Marie Glinel, Apr 2024, Aix-en -Provence, France |
|
De la sécurité à l'accès aux médicaments biologiques: les nouveaux enjeux prioritaires du biodroit de l'Union européenneQuel modèle pour le biodroit de l’Union européenne ?, Maria Fartunova- Michel, Mar 2024, Nancy, France |
|
Quel futur pour le cadre juridique des tissus et des organes destinés à la transplantation ? Le cas des organoïdesJournée d'étude du projet ITEGOREC, ITEGOREC, Jun 2023, Compiègne, France |
|
Challenges arising from the pharmaceutical strategy and beyondPanel discussion on EU pharmaceutical activity, EUHealthGov - The EU Health Governance Research Network, Jan 2023, Online, United Kingdom |
|
Les spécificités règlementaires des essais cliniques pour les médicaments innovantsSéminaire « Essais cliniques », Groupe de travail interdisciplinaire Maladies rares ; Mutation ; Méditerranée (GT3M) des instituts d’établissement d’Aix-Marseille université, SoMuM (Sociétés en Mutation en Méditerranée) et MarMaRa (Marseille Maladies Rares), Apr 2023, Marseille, France |
|
Update on contributions on EU law on medicinesEU Health Law Seminar “Evolving EU health law following the Covid-19 pandemic”, Maynooth University, Jun 2023, Maynooth, Ireland |
|
Roundtable on “Regulatory Revolution: Global Harmonization for Safe Personalized Medicines”International Society for Cell & Gene Therapy 2023 Annual Meeting, International Society for Cell & Gene Therapy, May 2023, Paris Palais des congrès, France |
|
Roundtable on “COVID-19 Hangover: How do we Regain the Trust in Research?”International Society for Cell & Gene Therapy 2023 Annual Meeting, International Society for Cell & Gene Therapy, May 2023, Paris Palais des congrès, France |
|
Challenges for the implementation of the current EU legal frameworks to organoidsBiotechnologies: towards collective wisdom: New forms of life: how should organoids be regulated?, TESaCo Colloquium, cycles d’étude de l’Académie des sciences morales et politiques, May 2023, En ligne, France |
|
Panel discussion on EU pharmaceutical activity: challenges arising from the pharmaceutical strategy and beyondSérie de séminaire du EU Health Governance Research Network, Jan 2023, En ligne, France |
|
Natalité et TranshumanismeLa natalité comme enjeu stratégique de politique de santé publique, 10ème Colloque international France-Chine, 8ème rencontre franco-chinoise de la santé, Bénédicte BEVIERE-BOYER; Xin CHEN, Dec 2022, Online, France |
|
Les organoïdes en action : Les aspects éthiques dans ORGANACT, projet de recherche interdisciplinaire en sciences sociales sur les organoïdesLes rencontres du GDR organoïdes, Dec 2022, Paris, France |
|
The pandemic Treaty from an EU law perspectiveRoundtable on “Access, equity and the relevance of the Pandemic Treaty: lessons from the COVID-19 response” 15th European Public Health Conference 2022, Elena Petelos, organisator of the roundtable, Nov 2022, Berlin, Germany |
|
The EuroGCT project and the potential involvement of EAHL membersMeeting of the EAHL Interest Group on Supranational Biolaw, Annual Conference of the European Association of Health Law, 20-22 April 2022, Apr 2022, Ghent, Belgium |
|
Presentation of the Joint Statement on “Health as a fundamental value. Towards an equitable and inclusive pharmaceutical strategy for the EU”EU Health Policy Platform Annual Meeting, May 2022, Brussels, Belgium |
|
Présentation du projet de recherche « Transhumansime: de nouveaux droits » Partie 2Conférence « Transhumansime: de nouveaux droits » Partie 2, May 2021, Aix-en-Provence, France |
|
Health as a fundamental value. Towards an equitable and inclusive pharmaceutical strategy for the EUEU Health Policy Platform Kick-off meeting, 2021 Thematic Networks, Sep 2021, Aix-en-Provence, France |
|
Les droits fondamentaux comme frontières de la médecine améliorative de l'humainColloque webinaire, "Le transhumanisme à l'ère de la médecine améliorative", May 2021, Virtual, France |
|
Le point de vue de juristes sur « Transhumansime :de nouveaux droits »Conférence « Transhumansime :de nouveaux droits » Partie 1, Mar 2021, Aix-en-Provence, France |
|
Activities of the EAHL IG on Supranational Biolaw in 2021-2022: Public consultation & Thematic NetworkMeeting of the EAHL Interest Group on Supranational Biolaw, 20 April 2022, Annual Conference of the European Association of Health Law, Ghent, Belgium, 20-22 April 2022., Apr 2021, Ghent, Belgium |
|
Les cellules souches et la recherche dans la révision de la loi relative à la bioéthiqueColloque « Regards croisés sur la loi de bioéthique », Oct 2021, Toulouse, France |
|
Le génome humain édité : risques et gouvernancee-colloque « Analyse des risques en santé : entre droit(s), sciences, éthique et attentes sociétales approches européenne et nationale », Journées Louis Dubouis, Mar 2021, Toulouse, France |
|
Bioconstitutionalism in the European Union regulation of gene-editing technologiesThe Global Summit organized by The International Forum on the Future of Constitutionalism, Jan 2021, Virtual, France |
|
Framing and Legitimating EU Legal Regulation of Human Gene-Editing Technologies: Key Facets and Functions of an ImaginaryVirtual Symposium of the Journal of law and the Biosciences on “Law, Biomedical Technoscience and Imaginaries”, Feb 2021, Virtual, France |
|
Présentation du projet de recherche "Transhumanisme: de nouveaux droits?Conférence « Transhumansime :de nouveaux droits » Partie 1, Mar 2021, Aix-en-Provence, France |
|
Proposal on “Health as a fundamental value. Towards an equitable and inclusive pharmaceutical strategy for the EU”EU Health Policy Platform Pitch webinar, 2021 Thematic Network semi-finalists, Jul 2021, Aix-en Provence, France |
|
La révision de la loi française relative à la bioéthique et les médicaments de thérapie innovanteRencontre « Médicaments de thérapie innovante » Eurobiomed, Sep 2021, Marseille, France |
|
Health as a fundamental value. Towards an inclusive and equitable pharmaceutical strategy for the EUHealth in Europe, Oct 2021, Virtual, France |
|
L’édition du génome humain face au droitConférence de l’Université Pour Tous, Oct 2020, Cahors, France |
|
Law and ethics beyond gene editing46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Aug 2020, Virtual, France |
|
Medicines as private goods for common use? An argumentation from medicines based on human biological elementsWorkshop on “The market for medicines in the face of unsatisfied needs: emergency adaptations or a reform on a permanent legal basis?”, Nov 2020, Dijon, France |
|
Introduction to the session on the values of biomedical innovationEuroScience Open Forum, Jul 2018, Toulouse, France |
|
Medical devices vs medicinal products: what is the impact of the recent European regulatory changes?Annual Meeting on Law & Society, Jun 2018, Toronto, Canada |
|
Médicaments de thérapie innovante et gestion des risques: quelle place pour le principe de précaution?Journées Louis Dubouis, Les nouveaux enjeux de la politique pharmaceutique européenne: pour des produits de santé sûrs, innovants et accessibles, N. de Grove-Valdeyron,, May 2018, Toulouse, France |
|
How can we facilitate the delivery of advanced therapies to patients?44th ANNUAL MEETING of the European Society for Blood and Marrow Transplantation (EBMT2108), Mar 2018, Lisbonne, Portugal |
|
The values of biomedical innovation: the legal viewEuroScience Open Forum, Jul 2018, Toulouse, France |
|
Legal and ethical controversies around medical uses of stem cells: Is Medical Ethics Really in the Best interest of the Patient?Extra Session on Stem Cells Ethics, Jun 2010, Uppsala, Sweden |
|
Transformer des cellules souches embryonnaires : quels enjeux éthiques et juridiques18th world Congress on Medical Law, Aug 2010, Zagreb, Croatia |
|
|
What regulatory pathways for health technologies using both medical devices and T&C in the European Union?European Society of Gene & Cell Therapy 2025, Oct 2025, Sevilla, Spain |
|
|
ATMPs: exceptional manufacturing returns to the patient's bedsideEuropean Society of Gene & Cell Therapy 2025, Oct 2025, Sevilla, Spain |
|
|
Financing and Structuring the Organoid and Organ-on-Chip Sector in France7th Congress of the French Society for Stem Cell Research, Nov 2025, Lyon (ENS Lyon), France |
|
|
Organoids and organs-on-chip in gene and cell therapy: which innovation strategies in France?European Society of Gene & Cell Therapy 2025, Oct 2025, Sevilla, Spain |
|
|
Obtaining cells for biomedical research and innovative therapies: which regulatory pathways in France?7th Congress of the French Society for Stem Cell Research, Nov 2025, Lyon (ENS Lyon), France |
|
|
A comparative study of national schemes and services for "early interaction" with RegulatorsEuropean Society of Gene & Cell Therapy 2025, Oct 2025, Sevilla, Spain |
|
|
Real access to ATMPs: the cost issueEuropean Society of Gene & Cell Therapy 2024, Oct 2024, Rome, Italy |
Organoids in action: an interdisciplinary approach in social sciences (Organact)Symposium on cortical and spinal organoids, Jan 2024, Paris, France |
|
Organoids in action: an interdisciplinary approach in social sciences (Organact)French Society for Stem Cell Research, 6th Annual Meeting, Jan 2024, Paris, France |
|
|
|
Expediting marketing authorization pathways for patients’ access to advanced therapiesEuropean Association of Health Law 2024, Sep 2024, Warsaw, Poland |
|
|
The Marketing Authorisation of Advanced Therapy Medicinal Products under the regulation of the European UnionInternational Society for Cell & Gene Therapy 2023 Annual Meeting, May 2023, Paris Palais des congrès, France. Abstract published in Cytotherapy, 25 (6 Supplement), pp.S160-S161, 2023 |
|
|
The challenges of Advanced Therapy Medicinal Products manufacturing in the European Union: Strengths and limits of current regulatory toolsEuropean Society for Gene & Cell Therapy Congress 2023, Oct 2023, Bruxelles (BEL), Belgium |
Comparing actors participating in the adoption process of SoHo and ATMP regulations at the European levelEuropean Society for Gene & Cell Therapy Congress 2023, Oct 2023, Bruxelles (BEL), Belgium |
|
|
|
Which actors to influence the adoption of EU guidelines for Advanced Therapy Medicinal Products?International Society for Cell & Gene Therapy 2023 Annual Meeting, May 2023, Paris Palais des congrès, France. Elsevier, Abstract published in Cytotherapy, 25 (6 Supplement), pp.S161, 2023 |
|
|
The European regulation on Health Technology Assessment Balancing European and National LevelsInternational Society for Cell & Gene Therapy 2023 Annual Meeting, May 2023, Paris Palais des congrès, France. Elsevier, Abstract published in Cytotherapy, 25 (6 Supplement), pp.S161, 2023 |
|
|
An exploratory analysis on the involvement of European organisations in the field of biomedical innovationEuropean Society for Gene & Cell Therapy Congress 2023, Oct 2023, Bruxelles (BEL), Belgium |
|
|
Illustrating regulatory requirements for the development of Gene and Cell therapy products with the EuroGCT research pathwaysEuropean Society for Blood and Marrow Transplant 49th annual meeting, Apr 2023, Paris, France |
Mapping the ATMPs Guidance LandscapeEuropean Society for Gene & Cell Therapy Congress 2023, Oct 2023, Bruxelles (BEL), Belgium |
|
|
|
Mapping regulators’ early interactions procedures to support innovationEuropean Society for Gene & Cell Therapy Congress 2023, Oct 2023, Bruxelles (BEL), Belgium |
|
|
Innovative therapy in European Parliament's positions: a numerical science-based vocabulary analysisEuropean Society for Gene & Cell Therapy Congress 2023, Oct 2023, Bruxelles (BEL), Belgium |
|
|
The new European regulation on Health Technology Assessment: what changes for Advanced Therapy Medicinal Products ?European Society for Gene & Cell Therapy Congress 2022, Oct 2022, Edinburgh, United Kingdom |
|
|
Comparative quality aspects of gene therapy medicinal products and medicinal products containing genetically modified cellsAnnual Conference of the European Association of Health Law, Apr 2022, Ghent, Belgium |
|
|
Bringing gene and cell therapies from lab to patients: the EuroGCT research pathwaysEuropean Society for Gene & Cell Therapy Congress 2022, Oct 2022, Edinburgh, United Kingdom |
|
|
The current revision of the orphan medicines regulation in the EU: what is at stake for gene and cell therapy?European Society for Gene & Cell Therapy Congress 2022, Oct 2022, Edinburgh, United Kingdom. |
|
|
Improving access to innovative medicines: proposals from national authorities to revise the European legislationEuropean Society for Gene & Cell Therapy Congress 2022, Oct 2022, Edinburgh, United Kingdom |
|
|
Production of ATMPs: What are the specificities for quality aspects ?European Society for Gene & Cell Therapy Congress 2022, Oct 2022, Edinburgh, United Kingdom. MARY ANN LIEBERT, INC140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801, 33 (23-24), pp.A196-A197, 2022 |
|
|
Specific guidelines requirements for clinical trials with Advanced Therapy Medicinal Products in the EUEuropean Society for Gene & Cell Therapy Congress 2022, Oct 2022, Edinburgh, United Kingdom. MARY ANN LIEBERT, 33 (23-24), pp.A197-A197, 2022 |
|
|
What are the quality challenges regarding comparibility considerations of Advanced Therapy Medicinal Products?Annual Conference of the European Association of Health Law, Apr 2022, Ghent, Belgium |
|
|
Production Aspects of Advanced Therapy Medicinal ProductsAnnual Conference of the European Association of Health Law, Apr 2022, Ghent, Belgium |
|
|
What specificity for the clinical aspects of investigational advanced therapy medicinal products?Annual Conference of the European Association of Health Law, Apr 2022, Ghent, Belgium |
|
|
Quality control and batch release aspects of Advanced Therapy Medicinal ProductsAnnual Conference of the European Association of Health Law (8th EAHL-Conference), Apr 2022, Ghent, Belgium |
|
|
ÉVALUATION À MI-PARCOURS DU PROJET DE RECHERCHE RELATIF AU TRANSHUMANISMEConférence « Transhumansime :de nouveaux droits » Parties 1 et 2, Mar 2021, Aix-en-Provence, France |
|
|
OBSERVATIONS SUR LA COMMUNICATION, LES RELATIONS INTERPERSONNELLES ET LES INTERACTIONS DANS LES CLASSES AUTOUR DE LA THEMATIQUE « TRANSHUMANISME ET DROIT »Conférence « Transhumansime :de nouveaux droits » Parties 1 et 2, Mar 2021, Aix-en-Provence, France |
|
|
La recherche sur « Transhumanisme : de nouveaux droits ? »Conférence « Transhumansime :de nouveaux droits » Partie 1 et Partie 2, Mar 2021, Aix-en-Provence, France |
|
|
Le sport augmenté, une révolution en marche à autoriser ?Transhumansime : de nouveaux droits, May 2021, Aix-en-Provence, France |
|
|
Des dispositifs médicaux au service du transhumanisme: jusqu’où doit-on aller ?Transhumansime : de nouveaux droits, May 2021, Aix-en-Provence, France |
|
|
Thérapie génique germinale et transhumanisme: entre amélioration de la qualité de vie et eugénismeConférence « Transhumansime :de nouveaux droits » Partie 2, May 2021, Aix-en-Provence, France |
|
|
Quels bébés pour demain?Transhumansime: de nouveaux droits, May 2021, Aix-en-Provence, France |
|
|
The delivery of advanced therapies to patients: challenges and solutionsEuroScience Open Forum, Jul 2018, Toulouse, France |
Dossier: Définitions et concepts du biodroitConfluence des droits_La revue, 2025 |
|
L’Humain médicamentQuaderni, 81, pp.1-94, 2013 |
Advanced Therapy Medicinal ProductsThe Oxford Encylopedia of EU Law [OEEUL], 2025, https://opil-ouplaw-com.lama.univ-amu.fr/display/10.1093/law-oeeul/law-oeeul-e230 |
|
|
|
MedicinesThe Oxford Encylopedia of EU Law [OEEUL], 2025, https://opil-ouplaw-com.lama.univ-amu.fr/display/10.1093/law-oeeul/law-oeeul-e231 |
Orphan medicinesOxford Encyclopedia of EU Law, 2023, https://opil.ouplaw.com/display/10.1093/law-oeeul/law-oeeul-e169 |
|
Marketing authorisation of generics, biosimilars, and hybrid medicinal productsThe Oxford Encylopedia of EU Law [OEEUL], 2022 |
|
Packaging and labelling of medicinesThe Oxford Encylopedia of EU Law [OEEUL], 2022 |
|
Manufacturing and batch testing of medicinesThe Oxford Encylopedia of EU Law, 2022 |
|
Transparency of medicines pricingThe Oxford Encylopedia of EU Law [OEEUL], 2022 |